Patents: Patent Strategies for Biotechnology Enterprises - A patent is an asset that can improve competitive advantage and boost profits, yet many biotech firms miss opportunities to take full strateg

ADVERTISEMENT

Patents: Patent Strategies for Biotechnology Enterprises
A patent is an asset that can improve competitive advantage and boost profits, yet many biotech firms miss opportunities to take full strategic advantage of their patents.


BioPharm International
Volume 20, Issue 8

BLOCKING STRATEGIES

A company should use both the defensive strategy of protecting its pre-existing core technology, as well as the offensive strategy of patenting claims covering future competitors from novel ideas of products, methods, or improvements.15 An intelligent offensive patent strategy can block future competition, secure emerging standards, increase an enterprise's valuation, collect licensing royalties, and forecast future trends of a certain product. For example, although its business model has since changed, the genomics enterprise Incyte acquired a substantial patent portfolio from patents on mostly novel, full-length genes and a few partial sequences obtained through its computer system. This strategy discourages competitors from taking similar inventions to market, and it allows the enterprise to collect potential licensing fees in the future.


Figure 1.
Blocking out competitors 100% is an ideal. It is unlikely that a biotechnology enterprise can develop a patent strategy that can protect it from competitors over a very long period of time. However, having an understanding of the ultimate or ideal techniques of protection can help the enterprise to identify ways to protect itself from competitors. Each link in the patent value chain provides opportunities to block competitors (Figure 1). Any link that is blocked from competitive access might be sufficient to protect the business. Combinations of blocking techniques over several links increase the probability of success. The objective of a blocking strategy is to find ways to protect each link in the patent value chain so that the competitor is denied access. Where that protection is not 100% certain, biotechnology companies want to make it difficult, time-consuming, or expensive to overcome the blocking factors.

CONCLUSION

Patents play a critical role in driving innovation and protecting advancements in the biotechnology sectors, and the need for strategic management of patents is greater than ever. Because the ultimate purpose of any good patent strategy is to serve the enterprise's overall business objectives, that strategy must be developed concurrently with research, development, and investment strategies. It certainly requires consistent business, technical, and legal collaboration. No generic system will work for every enterprise, so companies should be careful to establish patent strategies tailored to benefit their particular needs. A thorough and clear understanding of patent strategies may enable patentees or competitors to avoid the high stakes and costs of attacking and defending biotechnology patents.

ACKNOWLEDGEMENT

This research was supported by the JSPS of Japan and the National Nature Science Foundation of China, Project No. 70472060.

Wei Li is a doctoral candidate at the school of management at Huazhong University of Science and Technology, Wuhan 430074, Hubei Province, People's Republic of China, 0086.27.629.52.233,

Xiang Yu is a patent attorney and a professor of school of management at Huazhong University of Science and Technology, Wuhan 430074, Hubei Province, People's Republic of China, 0086.27.8755.6460,
.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here